Table 3.
Characteristics of neuroprotectant use
| Neuroprotectant | n (%*) |
|---|---|
| Edaravone | 95 (8.4) |
| Ganglioside GM1 | 29 (2.6) |
| Cattle encephalon glycoside and ignotin | 112 (9.9) |
| Cinepazide | 56 (5.0) |
| Citicholine | 334 (29.6) |
| Other† | 198 (17.5) |
| Unspecified | 321 (28.4) |
*As a proportion of all patients on any neuroprotectant therapy (n = 1130); groups are not mutually exclusive as 1 patient may be on more than 1 neuroprotectant
†Use of agents including deproteinised calf blood extracts, adenosine triphosphate, cerebroprotein extracts, cytidine disodium triphosphate, lysine, piracetam, meclofenoxate, and sodium fructose diphosphate.